Global Markets Direct Market Research Reports

Sort By :

Title	Published	Price
Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012 *By Global Markets Direct* Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2012'', provides an overview of the Muscle Invasive Bladder Cancer (MIBC) therapeutic	July 2012	$ 500
Refractory Multiple Myeloma – Pipeline Review, H2 2012 *By Global Markets Direct* Refractory Multiple Myeloma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Refractory Multiple Myeloma - Pipeline Review, H2 2012'', provides an overview of the Refractory Multiple Myeloma therapeutic pipeline. This report provides	July 2012	$ 500
Epithelial Ovarian Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Epithelial Ovarian Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Epithelial Ovarian Cancer - Pipeline Review, H2 2012'', provides an overview of the Epithelial Ovarian Cancer therapeutic pipeline. This report provides infor	July 2012	$ 500
B-Cell Leukemia – Pipeline Review, H2 2012 *By Global Markets Direct* B-Cell Leukemia – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''B-Cell Leukemia - Pipeline Review, H2 2012'', provides an overview of the B-Cell Leukemia therapeutic pipeline. This report provides information on the therapeutic deve	July 2012	$ 500
Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012 *By Global Markets Direct* Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H2 2012'', provides an overview of the Neuro Endocrine (Carcinoid) Carcinoma therapeutic	July 2012	$ 500
Malignant Neoplasms – Pipeline Review, H2 2012 *By Global Markets Direct* Malignant Neoplasms – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Malignant Neoplasms - Pipeline Review, H2 2012'', provides an overview of the Malignant Neoplasms therapeutic pipeline. This report provides information on the ther	July 2012	$ 500
Recurrent Malignant Glioma – Pipeline Review, H2 2012 *By Global Markets Direct* Recurrent Malignant Glioma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Recurrent Malignant Glioma - Pipeline Review, H2 2012'', provides an overview of the Recurrent Malignant Glioma therapeutic pipeline. This report provides in	July 2012	$ 500
Endobronchial Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Endobronchial Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Endobronchial Cancer - Pipeline Review, H2 2012'', provides an overview of the Endobronchial Cancer therapeutic pipeline. This report provides information on the t	July 2012	$ 500
Leiomyosarcoma – Pipeline Review, H2 2012 *By Global Markets Direct* Leiomyosarcoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Leiomyosarcoma - Pipeline Review, H2 2012'', provides an overview of the Leiomyosarcoma therapeutic pipeline. This report provides information on the therapeutic develop	July 2012	$ 500
Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012 *By Global Markets Direct* Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2012'', provides an overview of the Transitional Cell Cancer (	July 2012	$ 500
Esophageal Tumor – Pipeline Review, H2 2012 *By Global Markets Direct* Esophageal Tumor – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Esophageal Tumor - Pipeline Review, H2 2012'', provides an overview of the Esophageal Tumor therapeutic pipeline. This report provides information on the therapeutic d	July 2012	$ 500
Malignant Pleural Mesothelioma – Pipeline Review, H2 2012 *By Global Markets Direct* Malignant Pleural Mesothelioma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Malignant Pleural Mesothelioma - Pipeline Review, H2 2012'', provides an overview of the Malignant Pleural Mesothelioma therapeutic pipeline. This report	July 2012	$ 500
Brain Tumor – Pipeline Review, H2 2012 *By Global Markets Direct* Brain Tumor – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Brain Tumor - Pipeline Review, H2 2012'', provides an overview of the Brain Tumor therapeutic pipeline. This report provides information on the therapeutic development for	July 2012	$ 500
Colon Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Colon Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Colon Cancer - Pipeline Review, H2 2012'', provides an overview of the Colon Cancer therapeutic pipeline. This report provides information on the therapeutic development f	July 2012	$ 500
Hodgkin Lymphoma – Pipeline Review, H2 2012 *By Global Markets Direct* Hodgkin Lymphoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Hodgkin Lymphoma - Pipeline Review, H2 2012'', provides an overview of the Hodgkin Lymphoma therapeutic pipeline. This report provides information on the therapeutic d	July 2012	$ 500
Substance (Drug) Abuse – Pipeline Review, H2 2012 *By Global Markets Direct* Substance (Drug) Abuse – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Substance (Drug) Abuse - Pipeline Review, H2 2012'', provides an overview of the Substance (Drug) Abuse therapeutic pipeline. This report provides information on	July 2012	$ 500
Metastatic Pancreatic Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Metastatic Pancreatic Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Metastatic Pancreatic Cancer - Pipeline Review, H2 2012'', provides an overview of the Metastatic Pancreatic Cancer therapeutic pipeline. This report provi	July 2012	$ 500
Hepatic (Liver) Tumor – Pipeline Review, H2 2012 *By Global Markets Direct* Hepatic (Liver) Tumor – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Hepatic (Liver) Tumor - Pipeline Review, H2 2012'', provides an overview of the Hepatic (Liver) Tumor therapeutic pipeline. This report provides information on th	July 2012	$ 500
Diffuse Large B-Cell Lymphoma – Pipeline Review, H2 2012 *By Global Markets Direct* Diffuse Large B-Cell Lymphoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2012'', provides an overview of the Diffuse Large B-Cell Lymphoma therapeutic pipeline. This report pr	July 2012	$ 500
Ureter Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Ureter Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Ureter Cancer - Pipeline Review, H2 2012'', provides an overview of the Ureter Cancer therapeutic pipeline. This report provides information on the therapeutic developmen	July 2012	$ 500
Acute Lymphoblastic Lymphoma – Pipeline Review, H2 2012 *By Global Markets Direct* Acute Lymphoblastic Lymphoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Acute Lymphoblastic Lymphoma - Pipeline Review, H2 2012'', provides an overview of the Acute Lymphoblastic Lymphoma therapeutic pipeline. This report provi	July 2012	$ 500
Fallopian Tube Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Fallopian Tube Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Fallopian Tube Cancer - Pipeline Review, H2 2012'', provides an overview of the Fallopian Tube Cancer therapeutic pipeline. This report provides information on th	July 2012	$ 500
Low-Grade Astrocytoma – Pipeline Review, H2 2012 *By Global Markets Direct* Low-Grade Astrocytoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Low-Grade Astrocytoma - Pipeline Review, H2 2012'', provides an overview of the Low-Grade Astrocytoma therapeutic pipeline. This report provides information on th	July 2012	$ 500
Endometrial Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Endometrial Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Endometrial Cancer - Pipeline Review, H2 2012'', provides an overview of the Endometrial Cancer therapeutic pipeline. This report provides information on the therape	July 2012	$ 500
Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2012 *By Global Markets Direct* Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2012'', provides an overview of the Gastrointestinal Stromal Tumor (GIST) therapeutic	July 2012	$ 500
Stroke – Pipeline Review, H2 2012 *By Global Markets Direct* Stroke – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Stroke - Pipeline Review, H2 2012'', provides an overview of the Stroke therapeutic pipeline. This report provides information on the therapeutic development for Stroke, complet	July 2012	$ 500
Peritoneal Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Peritoneal Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Peritoneal Cancer - Pipeline Review, H2 2012'', provides an overview of the Peritoneal Cancer therapeutic pipeline. This report provides information on the therapeuti	July 2012	$ 500
Myocardial Infarction – Pipeline Review, H2 2012 *By Global Markets Direct* Myocardial Infarction – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Myocardial Infarction - Pipeline Review, H2 2012'', provides an overview of the Myocardial Infarction therapeutic pipeline. This report provides information on th	July 2012	$ 500
Metastatic Liver Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Metastatic Liver Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Metastatic Liver Cancer - Pipeline Review, H2 2012'', provides an overview of the Metastatic Liver Cancer therapeutic pipeline. This report provides information	July 2012	$ 500
Mantle Cell Lymphoma – Pipeline Review, H2 2012 *By Global Markets Direct* Mantle Cell Lymphoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Mantle Cell Lymphoma - Pipeline Review, H2 2012'', provides an overview of the Mantle Cell Lymphoma therapeutic pipeline. This report provides information on the t	July 2012	$ 500
Malignant Mesothelioma – Pipeline Review, H2 2012 *By Global Markets Direct* Malignant Mesothelioma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Malignant Mesothelioma - Pipeline Review, H2 2012'', provides an overview of the Malignant Mesothelioma therapeutic pipeline. This report provides information on	July 2012	$ 500
Rectal Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Rectal Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Rectal Cancer - Pipeline Review, H2 2012'', provides an overview of the Rectal Cancer therapeutic pipeline. This report provides information on the therapeutic developmen	July 2012	$ 500
Chemotherapy Effects – Pipeline Review, H2 2012 *By Global Markets Direct* Chemotherapy Effects – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Chemotherapy Effects - Pipeline Review, H2 2012'', provides an overview of the Chemotherapy Effects therapeutic pipeline. This report provides information on the t	July 2012	$ 500
Follicular Lymphoma – Pipeline Review, H2 2012 *By Global Markets Direct* Follicular Lymphoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Follicular Lymphoma - Pipeline Review, H2 2012'', provides an overview of the Follicular Lymphoma therapeutic pipeline. This report provides information on the ther	July 2012	$ 500
Sleep Disorders – Pipeline Review, H2 2012 *By Global Markets Direct* Sleep Disorders – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Sleep Disorders - Pipeline Review, H2 2012'', provides an overview of the Sleep Disorders therapeutic pipeline. This report provides information on the therapeutic deve	July 2012	$ 500
Neuroblastoma – Pipeline Review, H2 2012 *By Global Markets Direct* Neuroblastoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Neuroblastoma - Pipeline Review, H2 2012'', provides an overview of the Neuroblastoma therapeutic pipeline. This report provides information on the therapeutic developmen	July 2012	$ 500
Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2012 *By Global Markets Direct* Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2012'', provides an overview of the Cytomegalovirus (HHV-5) Infections therapeutic pipeline.	July 2012	$ 500
Arthritis – Pipeline Review, H2 2012 *By Global Markets Direct* Arthritis – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Arthritis - Pipeline Review, H2 2012'', provides an overview of the Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Arthri	July 2012	$ 500
Ischemia – Pipeline Review, H2 2012 *By Global Markets Direct* Ischemia – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Ischemia - Pipeline Review, H2 2012'', provides an overview of the Ischemia therapeutic pipeline. This report provides information on the therapeutic development for Ischemia,	July 2012	$ 500
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H2 2012 *By Global Markets Direct* Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2012'', provides an overview o	July 2012	$ 500
Muscle Wasting Disorders – Pipeline Review, H2 2012 *By Global Markets Direct* Muscle Wasting Disorders – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Muscle Wasting Disorders - Pipeline Review, H2 2012'', provides an overview of the Muscle Wasting Disorders therapeutic pipeline. This report provides informat	July 2012	$ 500
AIDS - Related Kaposi's Sarcoma – Pipeline Review, H2 2012 *By Global Markets Direct* AIDS - Related Kaposi''s Sarcoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''AIDS - Related Kaposi''s Sarcoma - Pipeline Review, H2 2012'', provides an overview of the AIDS - Related Kaposi''s Sarcoma therapeutic pipeline. This rep	July 2012	$ 500
Helicobacter Pylori Infections – Pipeline Review, H2 2012 *By Global Markets Direct* Helicobacter Pylori Infections – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Helicobacter Pylori Infections - Pipeline Review, H2 2012'', provides an overview of the Helicobacter Pylori Infections therapeutic pipeline. This report	July 2012	$ 500
Mycobacterium Avium-Intracellulare Infections – Pipeline Review, H2 2012 *By Global Markets Direct* Mycobacterium Avium-Intracellulare Infections – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Mycobacterium Avium-Intracellulare Infections - Pipeline Review, H2 2012'', provides an overview of the Mycobacterium Avium-Intracellulare	July 2012	$ 500
Clostridium Infections – Pipeline Review, H2 2012 *By Global Markets Direct* Clostridium Infections – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Clostridium Infections - Pipeline Review, H2 2012'', provides an overview of the Clostridium Infections therapeutic pipeline. This report provides information on	July 2012	$ 500
AIDS - Related Lymphoma – Pipeline Review, H2 2012 *By Global Markets Direct* AIDS - Related Lymphoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''AIDS - Related Lymphoma - Pipeline Review, H2 2012'', provides an overview of the AIDS - Related Lymphoma therapeutic pipeline. This report provides information	July 2012	$ 500
Angina (Angina Pectoris) – Pipeline Review, H2 2012 *By Global Markets Direct* Angina (Angina Pectoris) – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Angina (Angina Pectoris) - Pipeline Review, H2 2012'', provides an overview of the Angina (Angina Pectoris) therapeutic pipeline. This report provides informat	July 2012	$ 500
Urinary Tract Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Urinary Tract Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Urinary Tract Cancer - Pipeline Review, H2 2012'', provides an overview of the Urinary Tract Cancer therapeutic pipeline. This report provides information on the t	July 2012	$ 500
Anaplastic Astrocytoma – Pipeline Review, H2 2012 *By Global Markets Direct* Anaplastic Astrocytoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Anaplastic Astrocytoma - Pipeline Review, H2 2012'', provides an overview of the Anaplastic Astrocytoma therapeutic pipeline. This report provides information on	July 2012	$ 500
Penile Cancer – Pipeline Review, H2 2012 *By Global Markets Direct* Penile Cancer – Pipeline Review, H2 2012 Summary Global Markets Direct’s, ''Penile Cancer - Pipeline Review, H2 2012'', provides an overview of the Penile Cancer therapeutic pipeline. This report provides information on the therapeutic developmen	July 2012	$ 500

First

Last

Search for Market Research Reports:

Home › Publisher › Global Markets Direct

Global Markets Direct Market Research Reports

Start New Browse